US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Apimeds Pharmaceutical U.S, Inc.

3.76

-0.1200-3.09%

Volume:5K

Turnover:18.30K

Market Cap:5.67M

PE:-0.10

High:3.79

Open:3.79

Low:3.76

Close:3.88

52wk High:59.70

52wk Low:3.39

Shares:1.51M

Float Shares:304.73K

Volume Ratio:0.45

T/O Rate:1.59%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-38.5450

EPS(LYR):-0.1759

ROE:-144.99%

ROA:-69.29%

PB:0.70

PE(LYR):-21.38

Loading ...

Overview Company News Filings

Apimeds Pharmaceuticals US Settles With Inscobee; Merger Proceeds, $100 Million Pipe Financing to Close, and LŌKahi Therapeutics to Advance Apitox Program

THOMSON REUTERS

Apimeds Pharmaceuticals US Inc - Under Settlement, to Form New Wholly Owned Unit Within Seven Business Days

THOMSON REUTERS

Apimeds Pharmaceuticals US Inc - Lokahi to Pay $4 Mln to Apus Within Five Business Days

THOMSON REUTERS

Apimeds Pharmaceuticals US Inc - Appoints Sungjoon Chae as Co-Chief Executive Officer Effective May 4, 2026 - SEC Filing

THOMSON REUTERS

Apimeds Pharmaceuticals appoints Sungjoon Chae as co-CEO

Apimeds Pharmaceuticals Q4 EPS $(0.80) Down From $(0.50) YoY

Benzinga Earnings

Apimeds net loss widens to $6 million in FY25; revenue remains none

Apimeds Pharmaceuticals US Inc - Enters Settlement Agreement With Inscobee on April 24, 2026 - SEC Filing

THOMSON REUTERS

Apimeds Pharmaceuticals US Inc - Lokahi Retains All Rights to Apitox Program Including $2.2 Mln Prevail Cro Credit Facility - SEC Filing

THOMSON REUTERS

Apimeds Pharmaceuticals US settles merger dispute with Inscobee, Apimeds Korea

Apimeds Faces NYSE Non-Compliance Over Delayed 10-K Filing

Apimeds gets NYSE notice for late 10-K filing amid audit delay

Apimeds Pharmaceuticals Warns of Delayed 2025 Annual Report

Apimeds Pharmaceuticals expects delay in filing annual report, may miss 12b-25 extension

Apimeds says stockholder consent removing directors, CEO and CFO is void, amends 8-K

Apimeds Pharmaceuticals Delays Annual 10-K Filing

Apimeds Pharmaceuticals delays 2025 annual report filing, seeks 15-day SEC extension

Apimeds Pharmaceuticals US Challenges Disputed Boardroom Power Shift

BRIEF-Apimeds Pharmaceuticals Us Inc Vin Menon Continues To Serve As The Company’S Chief Executive Officer

Apimeds Pharmaceuticals US Inc: Vin Menon Continues to Serve as the Company’s Chief Executive Officer

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/APUS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"APUS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APUS\",,,,,undefined,":{"symbol":"APUS","market":"US","secType":"STK","nameCN":"Apimeds Pharmaceutical  U.S, Inc.","latestPrice":3.76,"timestamp":1788272053595,"preClose":3.88,"halted":0,"volume":4836,"delay":0,"changeRate":-0.03092783505154642,"floatShares":304730,"shares":1509119,"eps":-38.545,"marketStatus":"Trading","change":-0.12,"latestTime":"09-01 10:14:13 EDT","open":3.79,"high":3.79,"low":3.76,"amount":18296.2196664,"amplitude":0.007732,"askPrice":4.01,"askSize":100,"bidPrice":3.56,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-38.545,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788292800000},"marketStatusCode":2,"adr":0,"listingDate":1746763200000,"exchange":"AMEX","adjPreClose":3.88,"preHourTrading":{"tag":"盘前","latestPrice":3.685,"preClose":3.88,"latestTime":"09:16 EDT","volume":35,"amount":127.4159005,"timestamp":1788268571631,"change":-0.195,"changeRate":-0.050258,"amplitude":0.054124},"postHourTrading":{"tag":"盘后","latestPrice":3.88,"preClose":3.88,"latestTime":"19:55 EDT","volume":79,"amount":300.3025,"timestamp":1788220537828,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.446832},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APUS\",,,,,undefined,":{"symbol":"APUS","floatShares":304730,"roa":"-69.29%","roe":"-144.99%","lyrEps":-0.175862,"volumeRatio":0.446832,"shares":1509119,"dividePrice":0,"high":3.79,"amplitude":0.007732,"preClose":3.88,"low":3.76,"week52Low":3.39,"pbRate":"0.70","week52High":59.7,"institutionHeld":0,"latestPrice":3.76,"committee":0.333333,"eps":-38.545,"divideRate":0,"volume":4836,"delay":0,"ttmEps":-38.545,"open":3.79,"prevYearClose":16.4,"prevWeekClose":3.87,"prevMonthClose":3.88,"prevQuarterClose":9,"fiveDayClose":4.97,"twentyDayClose":4.92,"sixtyDayClose":12.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/APUS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-07-24","symbol":"APUS","defaultRemindTime":1784899800000,"type":"split","dateTimestamp":1784865600000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"APUS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"APUS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/APUS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"APUS","date":"2025-12-01","current":-0.097548,"percent":0.642384,"low":-37.866629,"twenty":-14.293061,"median":-12.284712,"eighty":-6.374893,"high":-4.754876,"avg":-11.953693,"sd":7.073766,"marketCap":36470350},"quantilePoints":[{"date":"2025-02-21","current":-34.716764,"twenty":-34.716764,"median":-34.716764,"eighty":-34.716764,"marketCap":57120291},{"date":"2025-02-28","current":-34.716764,"twenty":-34.716764,"median":-34.716764,"eighty":-34.716764,"marketCap":57120291},{"date":"2025-03-05","current":-34.716764,"twenty":-34.716764,"median":-34.716764,"eighty":-34.716764,"marketCap":57120291},{"date":"2025-05-09","current":-18.309826,"twenty":-34.716764,"median":-34.716764,"eighty":-33.299512,"marketCap":25450475},{"date":"2025-05-16","current":-14.148502,"twenty":-34.716764,"median":-34.008138,"eighty":-15.063993,"marketCap":19666276},{"date":"2025-05-23","current":-14.074662,"twenty":-34.716764,"median":-18.309826,"eighty":-14.306662,"marketCap":21054484},{"date":"2025-05-30","current":-13.387434,"twenty":-34.716764,"median":-15.063993,"eighty":-14.061031,"marketCap":20026450},{"date":"2025-06-06","current":-14.702962,"twenty":-34.716764,"median":-14.800251,"eighty":-13.996937,"marketCap":21994367},{"date":"2025-06-13","current":-14.314495,"twenty":-34.716764,"median":-14.564634,"eighty":-14.061031,"marketCap":21413253},{"date":"2025-06-20","current":-13.774354,"twenty":-33.866413,"median":-14.548195,"eighty":-14.0474,"marketCap":20605249},{"date":"2025-06-27","current":-13.296895,"twenty":-33.299512,"median":-14.356338,"eighty":-13.867215,"marketCap":19891011},{"date":"2025-07-03","current":-13.774354,"twenty":-27.303638,"median":-14.27266,"eighty":-13.727614,"marketCap":20605249},{"date":"2025-07-11","current":-14.006506,"twenty":-17.177946,"median":-14.161274,"eighty":-13.727614,"marketCap":20952529},{"date":"2025-07-18","current":-13.851738,"twenty":-15.354982,"median":-14.154888,"eighty":-13.727614,"marketCap":20721009},{"date":"2025-07-25","current":-16.173259,"twenty":-16.219689,"median":-14.161274,"eighty":-13.727614,"marketCap":24193804},{"date":"2025-08-01","current":-13.464818,"twenty":-16.219689,"median":-14.199966,"eighty":-13.727614,"marketCap":20142210},{"date":"2025-08-08","current":-12.14929,"twenty":-16.049445,"median":-14.148502,"eighty":-13.573156,"marketCap":18174293},{"date":"2025-08-15","current":-12.265366,"twenty":-15.710284,"median":-14.056061,"eighty":-13.418388,"marketCap":18347933},{"date":"2025-08-22","current":-7.697345,"twenty":-15.447843,"median":-14.006506,"eighty":-13.015991,"marketCap":28547481},{"date":"2025-08-29","current":-6.307075,"twenty":-15.306558,"median":-13.929122,"eighty":-12.721932,"marketCap":23391328},{"date":"2025-09-05","current":-6.307075,"twenty":-15.146611,"median":-13.929122,"eighty":-12.474303,"marketCap":23391328},{"date":"2025-09-12","current":-6.578348,"twenty":-15.038217,"median":-13.851738,"eighty":-12.234412,"marketCap":24397407},{"date":"2025-09-19","current":-6.205348,"twenty":-14.9276,"median":-13.774354,"eighty":-7.507455,"marketCap":23014048},{"date":"2025-09-26","current":-6.049367,"twenty":-14.889578,"median":-13.773581,"eighty":-6.849619,"marketCap":22435553},{"date":"2025-10-03","current":-5.832349,"twenty":-14.826776,"median":-13.69697,"eighty":-6.578348,"marketCap":21630690},{"date":"2025-10-10","current":-6.307075,"twenty":-14.675296,"median":-13.542202,"eighty":-6.472551,"marketCap":23391328},{"date":"2025-10-17","current":-6.239257,"twenty":-14.561346,"median":-13.50351,"eighty":-6.415584,"marketCap":23139808},{"date":"2025-10-24","current":-5.879822,"twenty":-14.548195,"median":-13.387434,"eighty":-6.358617,"marketCap":21806754},{"date":"2025-10-31","current":-6.917438,"twenty":-14.538909,"median":-13.039206,"eighty":-6.374893,"marketCap":25655005},{"date":"2025-11-07","current":-8.524725,"twenty":-14.481047,"median":-12.845746,"eighty":-6.381675,"marketCap":31616021},{"date":"2025-11-14","current":-9.460613,"twenty":-14.381444,"median":-12.652286,"eighty":-6.415584,"marketCap":35086992},{"date":"2025-11-21","current":-5.852155,"twenty":-14.312928,"median":-12.458826,"eighty":-6.415584,"marketCap":30182359},{"date":"2025-11-28","current":-7.071353,"twenty":-14.306662,"median":-12.304058,"eighty":-6.374893,"marketCap":36470350},{"date":"2025-12-01","current":-7.071353,"twenty":-14.293061,"median":-12.284712,"eighty":-6.374893,"marketCap":36470350}],"updateTime":1788272053957},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"APUS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633940234","title":"Apimeds Pharmaceuticals US Settles With Inscobee; Merger Proceeds, $100 Million Pipe Financing to Close, and LŌKahi Therapeutics to Advance Apitox Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2633940234","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633940234?lang=en_us&edition=fundamental","pubTime":"2026-05-06 02:07","pubTimestamp":1778004420,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nTUA9BF63J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633402689","title":"Apimeds Pharmaceuticals US Inc - Under Settlement, to Form New Wholly Owned Unit Within Seven Business Days","url":"https://stock-news.laohu8.com/highlight/detail?id=2633402689","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633402689?lang=en_us&edition=fundamental","pubTime":"2026-05-06 02:07","pubTimestamp":1778004420,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nTUA9BF63J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633250940","title":"Apimeds Pharmaceuticals US Inc - Lokahi to Pay $4 Mln to Apus Within Five Business Days","url":"https://stock-news.laohu8.com/highlight/detail?id=2633250940","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633250940?lang=en_us&edition=fundamental","pubTime":"2026-05-06 02:07","pubTimestamp":1778004420,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nTUA9BF63J:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633942275","title":"Apimeds Pharmaceuticals US Inc - Appoints Sungjoon Chae as Co-Chief Executive Officer Effective May 4, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2633942275","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633942275?lang=en_us&edition=fundamental","pubTime":"2026-05-06 00:31","pubTimestamp":1777998709,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nFWN41I0ZA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633942781","title":"Apimeds Pharmaceuticals appoints Sungjoon Chae as co-CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2633942781","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633942781?lang=en_us&edition=fundamental","pubTime":"2026-05-06 00:31","pubTimestamp":1777998664,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US appointed Sungjoon Chae as co-CEO, effective May 4, 2026.Chae is an architect and urban designer focused on large-scale real estate development and urban regeneration, with project experience across South Korea and US.He earned a Master of Architecture in Urban Design from Harvard University in 2013.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL9cpVCN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632956169","title":"Apimeds Pharmaceuticals Q4 EPS $(0.80) Down From $(0.50) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2632956169","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632956169?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:36","pubTimestamp":1777901805,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals (AMEX:APUS) reported quarterly losses of $(0.80) per share. This is a 60 percent decrease over losses of $(0.50) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52247578/apimeds-pharmaceuticals-q4-eps-0-80-down-from-0-50-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632937870","title":"Apimeds net loss widens to $6 million in FY25; revenue remains none","url":"https://stock-news.laohu8.com/highlight/detail?id=2632937870","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632937870?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:58","pubTimestamp":1777892303,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US posted a net loss of USD 6 million, widening from a net loss of USD 1.4 million.No revenue was generated; total operating expenses climbed to USD 11.9 million from USD 1.3 million.Research and development expense rose to USD 1.6 million from none, while general and administrative expense increased to USD 10.2 million from USD 1.3 million.Completed a May 12 IPO raising net proceeds of about USD 11.6 million; closed a Dec. 1 merger with MindWave adding digital assets valued at about USD 146.3 million, then drew a first tranche senior secured convertible note with USD 10 million gross proceeds.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL7Xrk8T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632934729","title":"Apimeds Pharmaceuticals US Inc - Enters Settlement Agreement With Inscobee on April 24, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2632934729","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632934729?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:18","pubTimestamp":1777889904,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nFWN41H06M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632347759","title":"Apimeds Pharmaceuticals US Inc - Lokahi Retains All Rights to Apitox Program Including $2.2 Mln Prevail Cro Credit Facility - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2632347759","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632347759?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:18","pubTimestamp":1777889904,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nFWN41H06M:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632934799","title":"Apimeds Pharmaceuticals US settles merger dispute with Inscobee, Apimeds Korea","url":"https://stock-news.laohu8.com/highlight/detail?id=2632934799","media":"Reuters","labels":["policyRegulatory","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632934799?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:16","pubTimestamp":1777889762,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US entered a confidential settlement on April 24, 2026, ending disputes tied to its December 1, 2025 merger agreement and related transactions.Lokahi Therapeutics will retain rights to Apitox program assets, including a Prevail CRO credit facility valued at about USD 2.2 million.Lokahi will pay USD 4 million in working capital within five business days of the settlement’s effective date, then forgive prior advances including a USD 750,000 February 2026 advance.Company will distribute 51% of Lokahi common stock as directed by former CEO Erik Emerson, with company retaining 49%.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL3WNx9W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629076550","title":"Apimeds Faces NYSE Non-Compliance Over Delayed 10-K Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2629076550","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629076550?lang=en_us&edition=fundamental","pubTime":"2026-04-23 05:59","pubTimestamp":1776895162,"startTime":"0","endTime":"0","summary":"An announcement from Apimeds Pharmaceuticals US, Inc. ( ($APUS) ) is now available. On April 17, 2026, Apimeds Pharmaceuticals US, Inc. received a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apimeds-faces-nyse-non-compliance-over-delayed-10-k-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apimeds-faces-nyse-non-compliance-over-delayed-10-k-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NYSE","APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629407378","title":"Apimeds gets NYSE notice for late 10-K filing amid audit delay","url":"https://stock-news.laohu8.com/highlight/detail?id=2629407378","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629407378?lang=en_us&edition=fundamental","pubTime":"2026-04-23 05:06","pubTimestamp":1776892016,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals received NYSE American notice of non-compliance tied to late filing of its annual report on Form 10-K for fiscal year ended Dec. 31, 2025.Delay was attributed to ongoing preparation of fourth-quarter and full-year financial statements, alongside additional time required for completion of audit procedures by its independent registered public accounting firm.Company expects to file Form 10-K by April 30, 2026.NYSE American will tag shares with “.LF” for late filing status, while an April 2, 2026 trading halt remains in effect.Exchange set initial cure period through Oct. 15, 2026, with potential for suspension and delisting if filings are not completed within allowed time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ad","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL4mbKJd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628244130","title":"Apimeds Pharmaceuticals Warns of Delayed 2025 Annual Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2628244130","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628244130?lang=en_us&edition=fundamental","pubTime":"2026-04-17 05:35","pubTimestamp":1776375345,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US, Inc. ( ($APUS) ) just unveiled an announcement. On March 31, 2026, Apimeds Pharmaceuticals US, Inc. disclosed that it h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apimeds-pharmaceuticals-warns-of-delayed-2025-annual-report?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apimeds-pharmaceuticals-warns-of-delayed-2025-annual-report?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628249106","title":"Apimeds Pharmaceuticals expects delay in filing annual report, may miss 12b-25 extension","url":"https://stock-news.laohu8.com/highlight/detail?id=2628249106","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628249106?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:31","pubTimestamp":1776371505,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals filed a Form 12b-25 on March 31, 2026, flagging a delay in its Form 10-K for fiscal year 2025.Management does not expect to file within Rule 12b-25’s 15-day extension window.Work remains on year-end financial statement preparation, while the independent auditor needs more time to complete audit procedures.NYSE American notice of noncompliance is expected due to missed 10-K filing deadline.Target filing date set for April 30, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 16,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDLbFBnqX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626113079","title":"Apimeds says stockholder consent removing directors, CEO and CFO is void, amends 8-K","url":"https://stock-news.laohu8.com/highlight/detail?id=2626113079","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626113079?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:31","pubTimestamp":1775766708,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals filed an amended Form 8-K to retract prior disclosure that majority stockholders removed several directors plus CEO Vin Menon and CFO Erick Frim on March 20, 2026.Company determined stockholder written consent was void under Delaware law plus contractual restrictions tied to merger-related support agreements.Filing cited improper use of 6,416,365 shares subject to an irrevocable proxy granted to company, making consent action ineffective.Apimeds also voided bylaw amendments purportedly adopted through same consent.Company plans to proceed with actions in its Schedule 14C information statement filed Feb. 27, 2026 and mailed March 5, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US I","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL2bFNQV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624356854","title":"Apimeds Pharmaceuticals Delays Annual 10-K Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624356854","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624356854?lang=en_us&edition=fundamental","pubTime":"2026-04-01 09:57","pubTimestamp":1775008629,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US, Inc. ( ($APUS) ) has released a notification of late filing. Apimeds Pharmaceuticals US, Inc. has notified regulators t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apimeds-pharmaceuticals-delays-annual-10-k-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apimeds-pharmaceuticals-delays-annual-10-k-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624440558","title":"Apimeds Pharmaceuticals delays 2025 annual report filing, seeks 15-day SEC extension","url":"https://stock-news.laohu8.com/highlight/detail?id=2624440558","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624440558?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:59","pubTimestamp":1774990773,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals filed notice it will miss deadline for its Form 10-K for fiscal year ended Dec. 31, 2025.Delay was attributed to additional time needed to prepare year-end financial statements.Independent auditor also requires more time to complete its review and audit.Company expects to file Form 10-K within 15-day extension period under SEC Rule 12b-25.Notice indicated no significant change in results of operations is expected versus prior-year period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLbJWm68:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622089178","title":"Apimeds Pharmaceuticals US Challenges Disputed Boardroom Power Shift","url":"https://stock-news.laohu8.com/highlight/detail?id=2622089178","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622089178?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:18","pubTimestamp":1774559937,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US, Inc. ( ($APUS) ) just unveiled an update. On March 20, 2026, Inscobee Inc. and Apimeds Inc. (Apimeds Korea) attempted b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apimeds-pharmaceuticals-us-challenges-disputed-boardroom-power-shift?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apimeds-pharmaceuticals-us-challenges-disputed-boardroom-power-shift?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4084","BK4234","APUS","PW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622990218","title":"BRIEF-Apimeds Pharmaceuticals Us Inc Vin Menon Continues To Serve As The Company’S Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2622990218","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622990218?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:52","pubTimestamp":1774558375,"startTime":"0","endTime":"0","summary":"BRIEF-Apimeds Pharmaceuticals Us Inc Vin Menon Continues To Serve As The Company’S Chief Executive OfficerApimeds Pharmaceuticals US Inc APUS.A:APIMEDS PHARMACEUTICALS US INC: VIN MENON CONTINUES TO SERVE AS THE COMPANY’S CHIEF EXECUTIVE OFFICERAPIMEDS PHARMACEUTICALS US INC: ERICK FRIM CONTINUES TO SERVE AS THE COMPANY’S CHIEF FINANCIAL OFFICERAPIMEDS PHARMACEUTICALS US:DOES NOT RECOGNIZE ALLEGED APPOINTMENT OF YOUNGJIK CHO AS ONE OF THE DIRECTORS MADE IN CONNECTION WITH STOCKHOLDER CONSENTSource text: [ID:n0001213900-26-034786]Further company coverage: APUS.A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E156:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622899776","title":"Apimeds Pharmaceuticals US Inc: Vin Menon Continues to Serve as the Company’s Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2622899776","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622899776?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:49","pubTimestamp":1774558177,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E156:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":53,"code":"91000000","status":"200"}]}}